Tekturna

Type: Product
Name: Tekturna
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis sales boosted by emerging markets and Gilenya

Novartis has posted a solid set financials for the second quarter, with net profit reaching $2.59 billion, up 3%, while group sales edged up 2% to $14.64 billion.Pharmaceutical turnover inched up 1% to $8.20 billion, hit by a 20% fall in sales of the ... [Published Pharma Times - Jul 17 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Novartis accused again of kickback tactics in new whistleblower suit

Kickback accusations have yet again been raised against Novartis, a company that four years ago promised to live by a new integrity code. Already embroiled with the Justice Department over accusations that it put together kickback schemes with pharmacies, ... [Published FiercePharma - Jul 08 2014]
First reported Jun 06 2014 - Updated Jun 06 2014 - 1 reports

GBI Research report shows key patent expiries to lead global anti-hypertensive market through fluctuating growth period by 2020

Multiple major drug patent expiries will cause the global anti-hypertensive market value to decline from $40 billion in 2013 to $37.6 billion by 2020, at a negative Compound Annual Growth Rate (CAGR) of 0.9 per cent says business intelligence provider ... [Published PharmaBiz - Jun 06 2014]
First reported Jun 03 2014 - Updated Jun 03 2014 - 1 reports

New Release on Breast Cancer Therapeutics in Major Developed Markets to 2020 by Researchmoz.us

ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs" to its huge collection of research reports. "Breast Cancer ... [Published PRWeb - Jun 03 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Tekturna Should Not Be Used In Combination With Certain Other Blood Pressure Drugs Due To Side Effects Hyperkalemia And Kidney Problems, Says Health Canada

In Addition, Such Combined Use In Patients With Kidney Disease Or Diabetes Increases Risks Of Having A Stroke As Well As Fainting And Falling (Posted by Tom Lamb at DrugInjuryWatch.com ) In February 2014 Health Canada issued new safety information ... [Published Drug Injury Watch - Mar 25 2014]

Quotes

...lawsuit that she was fired last year after suggesting the way Novartis proposed awarding a contract to McKesson for a study of cancer drug Afinitor "presented a conflict of interest and an appearance of kickbacks under the disguise of research."
ResearchMoz.us include new marketmarket research report "Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs" to its huge collection of research reports...
We have written in more detail about the increased risks of serious side effects associated with Tekturna in this 2012 article: "Tekturna And Other Aliskiren Related Blood Pressure Medications Can Cause Renal Failure, Kidney Complications, And Strokes"

More Content

All (5) | News (4) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Novartis sales boosted by emerging markets and ... [Published Pharma Times - Jul 17 2014]
Novartis accused again of kickback tactics in n... [Published FiercePharma - Jul 08 2014]
GBI Research report shows key patent expiries t... [Published PharmaBiz - Jun 06 2014]
New Release on Breast Cancer Therapeutics in Ma... [Published PRWeb - Jun 03 2014]
Tekturna Should Not Be Used In Combination With... [Published Drug Injury Watch - Mar 25 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tekturna Should Not Be Used In Combination With... [Published Drug Injury Watch - Mar 25 2014]
In Addition, Such Combined Use In Patients With Kidney Disease Or Diabetes Increases Risks Of Having A Stroke As Well As Fainting And Falling (Posted by Tom Lamb at DrugInjuryWatch.com ) In February 2014 Health Canada issued new safety information ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.